Roivant in-licenses HanAll's autoimmune candidate

HanAll Biopharma Co. Ltd. (KOSDAQ:009420) granted Roivant Sciences GmbH (Basel, Switzerland) exclusive rights to develop and commercialize HL161 to treat pathogenic IgG-mediated autoimmune diseases. HanAll will receive $30 million up front and $20 million in R&D funding over five years. The company is also eligible to receive up to $452.5 million in milestones, plus royalties. Roivant’s rights include North America, the EU, the U.K., Switzerland, Latin America, the Middle East and North Africa.

HL161 is in Phase I trials in Australia, which are expected to complete in 3Q18...